scholarly journals Treatment Outcomes among Patients with Extensively Drug‐Resistant Tuberculosis: Systematic Review and Meta‐Analysis

2010 ◽  
Vol 51 (1) ◽  
pp. 6-14 ◽  
Author(s):  
Karen R. Jacobson ◽  
Dylan B. Tierney ◽  
Christie Y. Jeon ◽  
Carole D. Mitnick ◽  
Megan B. Murray
Keyword(s):  
Systematic Review ◽  
Treatment Outcomes ◽  
Meta Analysis ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Extensively Drug Resistant

scholarly journals Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis

2019 ◽  
Vol 25 (3) ◽  
pp. 441-450 ◽  
Author(s):  
Muhammad Osman ◽  
Elizabeth P. Harausz ◽  
Anthony J. Garcia-Prats ◽  
H. Simon Schaaf ◽  
Brittany K. Moore ◽  
...  
Keyword(s):  
Systematic Review ◽  
Treatment Outcomes ◽  
Meta Analysis ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis ◽  
Extensively Drug Resistant

Linezolid for the treatment of extensively drug-resistant tuberculosis: a systematic review and meta-analysis

2019 ◽  
Vol 23 (12) ◽  
pp. 1293-1307 ◽  
Author(s):  
Z. Lifan ◽  
B. Sainan ◽  
S. Feng ◽  
Z. Siyan ◽  
L. Xiaoqing
Keyword(s):  
Systematic Review ◽  
Initial Dose ◽  
Meta Analysis ◽  
Treatment Success ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Sputum Culture Conversion ◽  
Resistant Tuberculosis ◽  
Extensively Drug Resistant ◽  
Culture Conversion

SETTING: Studies have shown that linezolid (LZD) can be used to treat extensively drug-resistant tuberculosis (XDR-TB).OBJECTIVE: To conduct a systematic review and meta-analysis to assess existing evidence concerning efficacy and safety of LZD for XDR-TB treatment.DESIGN: The MEDLINE@OVID, PubMed, EMBASE, the Cochrane Library, Clinical Trials, Sinomed, CMCI, CNKI, VIP and Wanfang databases were systematically searched for randomised controlled trials, cohort studies, case series or case reports on XDR-TB patients treated with LZD from January 2000 to December 2016. Summary estimates of the rate of sputum culture conversion, treatment success and adverse effects were calculated; data that could not be combined were summarised and described qualitatively. The combined results were examined for heterogeneity, sensitivity and publishing bias.RESULTS: Twenty-two original studies covering a total of 302 patients with XDR-TB fulfilled the inclusion criteria. Pooled estimates for sputum culture conversion and treatment success rates were respectively 93.2% and 67.4% in XDR-TB patients on LZD treatment. The pooled estimates for the rate of myelosuppression, peripheral neuropathy, optic neuritis and adverse reactions of the gastrointestinal tract were respectively 42.5%, 26.0%, 19.0% and 35.0%. Heterogeneity was mostly due to the initial dose of LZD (≤600 mg/d or >600 mg/d), as patients with a high initial dose of LZD were more likely to have myelosuppression (48.4% vs. 24.8%, P = 0.010) and adverse events of the gastrointestinal tract (41.3% vs.15.4%, P = 0.100).CONCLUSION: LZD appears to be effective for XDR-TB, but adverse events are common. An LZD dose of ≤600 mg/d as the initial dose for treating XDR-TB patients is recommended.

scholarly journals The Prevalence of Drug-Resistant Tuberculosis in Mainland China: An Updated Systematic Review and Meta-Analysis

PLoS ONE ◽  
2016 ◽  
Vol 11 (2) ◽  
pp. e0148041 ◽  
Author(s):  
Qionghong Duan ◽  
Zi Chen ◽  
Cong Chen ◽  
Zhengbin Zhang ◽  
Zhouqin Lu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Mainland China ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis

Status of drug-resistant tuberculosis in China: A systematic review and meta-analysis

2016 ◽  
Vol 44 (6) ◽  
pp. 671-676 ◽  
Author(s):  
Jingya Zhang ◽  
Haimei Gou ◽  
Xuejiao Hu ◽  
Xin Hu ◽  
Mengqiao Shang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Meta Analysis ◽  
Drug Resistant ◽  
Drug Resistant Tuberculosis ◽  
Resistant Tuberculosis
Sign in / Sign up

Export Citation Format

Share Document